您的位置: 首页 > 2023年4月 第54卷 第4期 > 文字全文
2023年7月 第38卷 第7期11
目录

化疗联合调强放疗治疗老年(≥65岁)局部晚期鼻咽癌的临床疗效

Clinical efficacy of chemotherapy combined with intensity-modulated radiotherapy in the treatment of elderly(≥65 years old)locally advanced nasopharyngeal carcinoma

来源期刊: 广州医药 | 40-44 发布时间:2023-05-18 收稿时间:2025/11/13 18:35:30 阅读量:31
作者:
关键词:
调强放疗化疗老年局部晚期鼻咽癌
intensity-modulated radiotherapychemotherapyelderlylocally advanced nasopharyngeal carcinoma
DOI:
10.3969/j.issn.1000-8535.2023.04.007
收稿时间:
2022-06-27 
修订日期:
 
接收日期:
 
引用总数:
6  
目的 探析化疗联合调强放疗(IMRT)治疗老年(≥65岁)局部晚期鼻咽癌的临床效果。方法 选取2018年1月—2019年1月我院诊治的90例老年局部晚期鼻咽癌患者为研究对象,使用随机数表法将此90例患者分为观察组及对照组,各45例。观察组行IMRT,对照组行化疗联合IMRT,对比2组的效果。结果 2组的治疗总有效率均为100%,组间差异不显著(P<0.05)。观察组的生活质量改善率(93.33%)高于对照组(77.78%)(P<0.05)。对照组出现3~4级白细胞减少、呕吐、黏膜炎人数明显高于观察组(P<0.05),两者其他毒副反应比较无显著差异(P>0.05)。观察组的1年总体生存率(91.11%)及3年总体生存率(75.56%)均高于对照组(86.67%、68.89%)(P<0.05)。结论 对于老年局部晚期鼻咽癌,化疗联合IMRT相比单纯IMRT降低了远期生存率,增加了毒副反应并影响疗后生活质量的改善,不宜常规应用,单纯IMRT可能是更合适的治疗选择。
Objective To explore the clinical effect of chemotherapy combined with intensity modulated radiation therapy(IMRT)in the treatment of elderly(≥65 years old)locally advanced nasopharyngeal carcinoma.Methods The study was carried out from January 2018 to January 2019.During this period,90 elderly patients with locally advanced nasopharyngeal carcinoma who were diagnosed and treated in our hospital were selected as the research objects.The random number table method was used to divide the 90 patients into observation groups,and the control group,each with 45 cases.The observation group was treated with IMRT,and the control group was treated with chemotherapy combined with IMRT.The effects of the two groups were compared.Results The total effective rate of the two groups was 100%,and there was no significant difference between the two groups(P<0.05).The improvement rate of quality of life in the observation group(93.33%)was higher than that in the control group(77.78%,P<0.05).The number of grade 3-4 leukopenia,vomiting and mucositis in the control group was significantly higher than that in the observation group(P<0.05),and there was no significant difference in other side effects between the two groups(P>0.05).The 1-year overall survival rate(91.11%)and 3-year overall survival rate(75.56%)of the observation group were higher than those of the control group(86.67%,68.89%,P<0.05).Conclusions For locally advanced nasopharyngeal carcinoma in the elderly,chemotherapy combined with IMRT reduces the long-term survival rate,increases the toxic and side effects and affects the improvement of the quality of life after treatment.It is not suitable for routine application,and IMRT alone may be a more appropriate treatment choice.
1、 李媛媛,岑妍芳,吴伟莉,等.调强放射治疗时代下老年鼻咽癌患者的临床特点及预后[J].重庆医学,2019,48(10):1688-1692. 李媛媛,岑妍芳,吴伟莉,等.调强放射治疗时代下老年鼻咽癌患者的临床特点及预后[J].重庆医学,2019,48(10):1688-1692.
2、 王琦琪,史尚雨宸,信亚晨,等.化疗联合调强放疗治疗老年(≥65岁)局部晚期鼻咽癌的疗效及安全性[J].现代肿瘤医学,2022,30(7):1202-1206. 王琦琪,史尚雨宸,信亚晨,等.化疗联合调强放疗治疗老年(≥65岁)局部晚期鼻咽癌的疗效及安全性[J].现代肿瘤医学,2022,30(7):1202-1206.
3、 CAI H,PANG X,DONG D,et al.Molecular Decision Tree Algorithms Predict Individual Recurrence Pattern for Locally Advanced Nasopharyngeal Carcinoma[J].Journal of Cancer,2019,10(15):3323-3332. CAI H,PANG X,DONG D,et al.Molecular Decision Tree Algorithms Predict Individual Recurrence Pattern for Locally Advanced Nasopharyngeal Carcinoma[J].Journal of Cancer,2019,10(15):3323-3332.
4、 WU Y,WEI X Y,YUAN Z L,et al.Phase Ⅱ study of induction chemotherapy followed by concurrent chemoradiotherapy with raltitrexed and cisplatin in locally advanced nasopharyngeal carcinoma[J].Chin J Cancer Res,2020,32(5):665-672. WU Y,WEI X Y,YUAN Z L,et al.Phase Ⅱ study of induction chemotherapy followed by concurrent chemoradiotherapy with raltitrexed and cisplatin in locally advanced nasopharyngeal carcinoma[J].Chin J Cancer Res,2020,32(5):665-672.
5、 舒宏博,金风,吴伟莉,等.同期放化疗联合诱导或辅助时辰化疗治疗局部晚期鼻咽癌的临床观察[J].临床肿瘤学杂志,2021,26(7):615-621. 舒宏博,金风,吴伟莉,等.同期放化疗联合诱导或辅助时辰化疗治疗局部晚期鼻咽癌的临床观察[J].临床肿瘤学杂志,2021,26(7):615-621.
6、 杨婕,梁忠国,江雨婷,等.鼻咽癌调强放疗时代诱导化疗后序贯放疗±同步化疗疗效与安全性的 Meta分析[J].中华放射肿瘤学杂志,2022,31(3):229-235. 杨婕,梁忠国,江雨婷,等.鼻咽癌调强放疗时代诱导化疗后序贯放疗±同步化疗疗效与安全性的 Meta分析[J].中华放射肿瘤学杂志,2022,31(3):229-235.
7、 OU O,WANG X S,WU M Y,et al.Prognostic value of post-radiotherapy neutrophil-to-lymphocyte ratio in locally advanced nasopharyngeal carcinoma[J].Strahlentherapie und Onkologie,2021,196(3):252-261. OU O,WANG X S,WU M Y,et al.Prognostic value of post-radiotherapy neutrophil-to-lymphocyte ratio in locally advanced nasopharyngeal carcinoma[J].Strahlentherapie und Onkologie,2021,196(3):252-261.
8、 江杭,金风,吴伟莉,等.调强放疗联合时辰化疗治疗局部进展期鼻咽癌的近期疗效及不良反应[J].中华放射医学与防护杂志,2019(11):813-819. 江杭,金风,吴伟莉,等.调强放疗联合时辰化疗治疗局部进展期鼻咽癌的近期疗效及不良反应[J].中华放射医学与防护杂志,2019(11):813-819.
9、 刘宽奇,金风,江杭,等.时辰化疗与常规化疗联合调强放疗治疗局部晚期鼻咽癌的随访结果分析[J].中华肿瘤杂志,2020(2):133-138. 刘宽奇,金风,江杭,等.时辰化疗与常规化疗联合调强放疗治疗局部晚期鼻咽癌的随访结果分析[J].中华肿瘤杂志,2020(2):133-138.
10、 杨飞,蒋晓平,陈天宾,等.替吉奥联合同步推量调强放疗对老年局部晚期鼻咽癌疗效和免疫功能的影响[J].老年医学与保健,2019,25(5):658-660,664. 杨飞,蒋晓平,陈天宾,等.替吉奥联合同步推量调强放疗对老年局部晚期鼻咽癌疗效和免疫功能的影响[J].老年医学与保健,2019,25(5):658-660,664.
11、 张榕珂,李涛,吕家华,等.预后营养指数联合系统免疫炎症指数对预测食管鳞癌根治性同步放化疗/放疗患者生存的临床价值[J].肿瘤预防与治疗,2022,35(3):235-243. 张榕珂,李涛,吕家华,等.预后营养指数联合系统免疫炎症指数对预测食管鳞癌根治性同步放化疗/放疗患者生存的临床价值[J].肿瘤预防与治疗,2022,35(3):235-243.
12、 张钦华,利锦燕,邹雨荷,等.TP方案诱导化疗联合调强放疗治疗局部中晚期鼻咽癌的疗效观察[J].广西医科大学学报,2019,36(7):1134-1139. 张钦华,利锦燕,邹雨荷,等.TP方案诱导化疗联合调强放疗治疗局部中晚期鼻咽癌的疗效观察[J].广西医科大学学报,2019,36(7):1134-1139.
13、 冯成军,陈绍俊,蒙以良,等.诱导化疗联合同期调强放化疗与同期调强放化疗联合辅助化疗治疗局部晚期鼻咽癌的疗效[J].肿瘤,2019,39(10):823-831. 冯成军,陈绍俊,蒙以良,等.诱导化疗联合同期调强放化疗与同期调强放化疗联合辅助化疗治疗局部晚期鼻咽癌的疗效[J].肿瘤,2019,39(10):823-831.
14、 周亚娟,牟艳花,胡德胜.Ⅱ~Ⅳa期鼻咽癌根治性放化疗-2021年CSCO/ASCO国际循证指南解读[J].肿瘤防治研究,2021,48(5):10. 周亚娟,牟艳花,胡德胜.Ⅱ~Ⅳa期鼻咽癌根治性放化疗-2021年CSCO/ASCO国际循证指南解读[J].肿瘤防治研究,2021,48(5):10.
15、 罗秀玲,金风,毕婷,等.TPF方案诱导化疗不同给药方式联合调强放疗治疗局部晚期鼻咽癌的中期疗效及预后分析[J].中华放射医学与防护杂志,2018,38(8):595-601. 罗秀玲,金风,毕婷,等.TPF方案诱导化疗不同给药方式联合调强放疗治疗局部晚期鼻咽癌的中期疗效及预后分析[J].中华放射医学与防护杂志,2018,38(8):595-601.
16、 殷蔚伯. 肿瘤放射治疗学[M].北京:中国协和医科大学出版社,2008. 殷蔚伯. 肿瘤放射治疗学[M].北京:中国协和医科大学出版社,2008.
1、席颖,魏少贤. 不同化疗方案与调强放疗同期治疗局部晚期鼻咽癌的疗效评价[J]. 黑龙江医学,2025,49(13):1596-1598. DOI:10.3969/j.issn.1004-5775.2025.13.018.席颖,魏少贤. 不同化疗方案与调强放疗同期治疗局部晚期鼻咽癌的疗效评价[J]. 黑龙江医学,2025,49(13):1596-1598. DOI:10.3969/j.issn.1004-5775.2025.13.018.
2、吕得刚,黄嵘.鼻咽癌患者调强放射治疗后颞颌关节损伤和影响因素观察[J].当代临床医刊,2023,36(04):9-10. 吕得刚,黄嵘.鼻咽癌患者调强放射治疗后颞颌关节损伤和影响因素观察[J].当代临床医刊,2023,36(04):9-10.
3、方喜生,刘霞,王秀艳,等.化疗联合NKG2A抑制剂抗头颈部鳞状细胞癌作用的研究[J].广州医药,2024,55(08):860-868. 方喜生,刘霞,王秀艳,等.化疗联合NKG2A抑制剂抗头颈部鳞状细胞癌作用的研究[J].广州医药,2024,55(08):860-868.
4、车亚,任英红,郭峰,等.鼻咽癌放疗患者显著体重丢失的列线图模型构建及验证[J].国际医药卫生导报,2024,30(19):3229-3235. 车亚,任英红,郭峰,等.鼻咽癌放疗患者显著体重丢失的列线图模型构建及验证[J].国际医药卫生导报,2024,30(19):3229-3235.
5、万春玲,邓淑琴,谌根妹,等.改良定位式鼻咽冲洗器在鼻咽癌放疗后溃疡中的应用效果观察[J].临床医药实践,2025,34(02):156-160.DOI:10.16047/j.cnki.cn14-1300/r.2025.02.017. 万春玲,邓淑琴,谌根妹,等.改良定位式鼻咽冲洗器在鼻咽癌放疗后溃疡中的应用效果观察[J].临床医药实践,2025,34(02):156-160.DOI:10.16047/j.cnki.cn14-1300/r.2025.02.017.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录